30 Apr

With New Data, Karyopharm Says It Will Ask for Myeloma Approval

Credit: Depositphotos image_5645691_chepko

Karyopharm Therapeutics (NASDAQ: KPTI) reported this afternoon that its cancer drug selinexor has passed a big test in treating some of the most desperate multiple myeloma patients-those who have failed at least five other therapies. The Newton, MA-based company will ask U.S. and European drug regulators to consider selinexor for approval.

Karyopharm (NASDAQ: KPTI) reports that selinexor has succeeded in a Phase 2B study called STORM, which tested the drug in 122 “penta-refractory” patients. According to Karyopharm, 25.4 percent of the penta-refractory patients responded to treatment with selinexor and dexamethasone, and those responses lasted a median of 4.4 months…. Read more »

UNDERWRITERS AND PARTNERS

          

          

            

30 Apr

BUILDING A LOW-CARBON, CLIMATE RESILIENT FUTURE: SECURE, CLEAN AND EFFICIENT ENERGY

[Source: http://ec.europa.eu/health/ageing/innovation/index_en.htm] Identifier: H2020-LC-SC3-2018-2019-2020Pillar: Societal ChallengesPlanned Opening Date: Deadline: Wed, 16 Oct 2019 17:00:00 (Brussels local time)Modification Date: Mon, 30 Apr 2018Latest information:

Normal
0

false
false
false

EN-GB
X-NONE
X-NONE

MicrosoftInternetExplorer4

/* Style Definitions */
table.MsoNormalTable
{mso-style-name:”Table Normal”;
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-priority:99;
mso-style-parent:””;
mso-padding-alt:0cm 5.4pt 0cm 5.

30 Apr

60 Minutes Shines Spotlight on the Power and Promise of CRISPR

On Sunday night, 60 Minutes ran a captivating segment on the promise and possibilities of CRISPR – the revolutionary, cutting-edge technology used to delete, insert, or repair DNA in humans. “There are about six thousand or more diseases that are caused by faulty genes. The hope is that we will be able to address most, if not all of them,” Feng Zhang of the Broad Institute told 60 Minutes. Catch the full segment here.

Click to Watch

To learn more about genome editing and its potential to produce transformative breakthroughs in both human health and agriculture, head over to our new issue page. We provide important resources and background materials to better understand these groundbreaking innovations and what is needed to ensure the policy and regulatory environments are keeping pace with the scientific advances happening in labs across the nation.

Check it out here.

30 Apr

Soy industry tries to speed up biotech approval process in China

Biotech trade approval has always been a challenge for us particularly with China and the EU and I’m always interested in hearing about why it takes so long,” ​Doug Winters, a member of the visiting delegation, US Soybean Export Council (USSEC) board member and United Soybean Board (USB) …

28 Apr

Alder BioPharmaceuticals Appoints Erin Lavelle to New COO Role

Alder BioPharmaceuticals (NASDAQ: ALDR) has named Erin LaVelle to the newly created position of chief operating officer. Before joining Bothell, WA-based Alder, Lavelle was the general manager of the Taiwanese affiliate of Amgen (NASDAQ: AMGN). Alder says Lavelle will lead strategy and planning as the company prepares to bring its migraine drug, eptinezumab, to the market. The company has said it expects to file for FDA approval of the migraine drug later this year.

UNDERWRITERS AND PARTNERS

          

          

            

27 Apr

New CRISPR Startup from Feng Zhang Revealed

With all the buzz this week about the new CRISPR diagnostic startup from the University of California, Berkeley lab of Jennifer Doudna, perhaps it shouldn’t be a surprise that news of another CRISPR startup-this one associated with another CRISPR pioneer, Feng Zhang-is now coming out. The Boston Business Journal reports today that Zhang of the Broad Institute has co-founded Beam Therapeutics and that the company has raised the first $13 million of a Series A round of financing. The article cites Pitchbook for the dollar figure.

A Beam spokesperson declined to comment for the article. But the article cites a source who… Read more »

UNDERWRITERS AND PARTNERS

          

          

            

27 Apr

Better Health and care, economic growth and sustainable health systems

[Source: http://ec.europa.eu/health/ageing/innovation/index_en.htm] Identifier: H2020-SC1-BHC-2018-2020Pillar: Societal ChallengesOpening Date: Deadline: Tue, 6 Feb 2018 17:00:00 (Brussels local time)Modification Date: Fri, 27 Apr 2018Latest information: The submission of proposals to the 21 topics of H2020-SC1-2018-Single-Stage-RTD closed on 18 April 2018. A total of 324 proposals were submitted. The number of proposals per topic is as follows:
– SC1-BHC-03-2018 (RIA): 27
– SC1-BHC-04-2018 (COFUND-EJP): 1
– SC1-BHC-05-2018 (RIA): 19
– SC1-BHC-09-2018 (RIA): 63
– SC1-BHC-16-2018 (RIA): 24
– SC1-BHC-18-2018 (RIA): 41
– SC1-BHC-21-2018 (RIA): 19
– SC1-BHC-23-2018 (RIA): 45
– SC1-BHC-26-2018 (RIA): 9
– SC1-BHC-27-2018 (RIA): 28
– SC1-HCO-01-2018-2019-2020 (CSA): 9
– SC1-HCO-02-2018 (CSA): 1
– SC1-HCO-04-2018 (ERA-NET-Cofund): 2
– SC1-HCO-05-2018 (CSA): 2
– SC1-HCO-06-2018 (CSA): 5
– SC1-HCO-08-2018 (CSA): 2
– SC1-HCO-09-2018 (CSA): 11
– SC1-HCO-10-2018 (CSA): 2
– SC1-HCO-11-2018 (CSA): 7
– SC1-HCO-12-2018 (CSA): 3
– SC1-HCO-13-2018 (CSA): 4

27 Apr

New Book Makes a Persuasive Case for GM by a Man Who Used to Oppose It

It’s hard to change your views when you are passionate about something, explains Devang Mehta for Massive. For scientists working on climate change, vaccines, evolution, and GMOs, this tendency of significant sections of the public to resist facts that run counter to their existing beliefs can be extremely frustrating.

This is why environmentalist Mark Lynas’ new book, Seeds of Science: Why we got it so wrong on GMOs, is such a welcome read:  it gives us a peek into the process of changing one’s dearly held opinions, from someone who did so very publicly.

Lynas is perhaps most famous for getting up at the 2013 Oxford Farming Conference (an annual farming conference in the UK that first started in 1936) and giving a speech beginning, “For the record, here and upfront, I apologize for having spent several years ripping up GM crops… I now regret it completely.” Five years on, in his new book, Lynas walks us through this remarkable conversion with disarming, and sometimes brutal, honesty.

The book begins in 1999, with a post-midnight skulk around in a testing site of GM maize somewhere in eastern England. Lynas and a dozen other British activists, dressed in black and improbably armed with machetes and other “sharp tools,” are slashing the “living pollution” that is GM maize, when they’re rudely interrupted by the police.

Over the 250-odd pages that follow, Lynas introduces us to an eclectic cast of characters, including Vandana Shiva (the face of the anti-GMO movement), George Monbiot (the famed Guardian columnist, and an old anti-GMO comrade-in-arms), Paul Kingsnorth (a Man Booker long-listed novelist, who in the book, doubles as Lynas’ antithesis), Professor Marc Van Montagu (one of the inventors of GM technology), Dr. Leena Tripathi (a Kenyan scientist working on bananas), and Grace Rehema (a Tanzanian cassava farmer). He deftly uses his personal and professional relationships with these figures to narrate the story, first of how he came to repudiate his former allies and their beliefs, and then to describe his activities in the five years since.

As someone working in the field, I opened the book expecting to be bored by a repetition of often stale arguments and stories. After all, how much could Lynas really add in a debate that’s been raging for more than 30 years? Color me surprised!

Overall this is a book I wish could be found and read in every classroom and every university library. It’s an honest and thorough accounting of the science, issues, and emotions involved in the GMO debate, as well as the impact that perceptions of the technology in Europe have in poorer parts of the world. Mark Lynas accurately dissects the differences in thinking between scientists and activists that have stymied any agreement on GMOs for the last 20 years.

However, as I read the last, and possibly most anodyne, paragraph of Seeds of Science, I found myself, much like the author, caught between two worldviews, with more questions than answers about the future of GMOs  -  a technology that I’m still hoping reaches those who need it the most.

26 Apr

Exact Sciences Beats Quarterly Forecasts, Sending Its Stock Price Up

When leaders at Exact Sciences discussed dealing with the adversity of cold weather and a “historically severe” flu season in early 2018, some industry observers predicted a potential break in the long growth streak of the Madison, WI-based company’s flagship product, a stool-based DNA test for colorectal cancer known as Cologuard.

But on Thursday, Exact (NASDAQ: EXAS) said it completed 186,000 Cologuard tests during the three-month period ending March 31. The quarterly total beat the company’s projection in February that it would complete between 176,000 and 181,000 Cologuard tests in the first quarter.

Exact develops diagnostic tests for several types… Read more »

UNDERWRITERS AND PARTNERS

          

          

            

26 Apr

2018-2020 Mobility for Growth

[Source: http://ec.europa.eu/health/ageing/innovation/index_en.htm] Identifier: H2020-MG-2018-2019-2020Pillar: Societal ChallengesPlanned Opening Date: Deadline: Wed, 24 Apr 2019 17:00:00 (Brussels local time)Modification Date: Thu, 26 Apr 2018Latest information:
For 2018 two-stage topics,the submission session for stage-2 proposals will open on 2 May 2018.